Top Markets
Coin of the day
Valeo Pharma Inc. Valeo Pharma Inc.

Valeo Pharma Inc.

VPHIF
Clasificación en acciones #41805
Valeo Pharma Inc. is a Canadian specialty pharmaceutical firm dedicated to... Valeo Pharma Inc. is a Canadian specialty pharmaceutical firm dedicated to sourcing, licensing, and selling a variety of medicinal products, with a primary emphasis on respiratory, specialized, and hospital-grade generic drugs. Its extensive product lineup features prominent asthma medications like Enerzair Breezhaler (a triple-combination LABA/LAMA/ICS) and Atectura Breezhaler (a dual-combination LABA/ICS). The company also offers Redesca, crucial for preventing and treating deep vein thrombosis and pulmonary embolism. For neurological conditions, Valeo markets Onstryv, an add-on treatment for Idiopathic Parkinson's Disease in patients on stable Levodopa, and Benztropine, an anticholinergic for PD. Pain management is addressed with M-Eslon, an extended-release morphine sulfate, while Yondelis targets soft tissue sarcoma. Beyond these, the portfolio includes Hesperco, an immune-supporting bioflavonoid antioxidant; Ametop, a skin anesthetic used before venous procedures; Ethacrynate Sodium, a loop diuretic for high blood pressure and swelling; and Amikacin, an injectable antibiotic. Founded in 2003, Valeo Pharma Inc. is headquartered in Kirkland, Canada.
Precio por acción
$0.0001
Última sincronización: 2026-08-11
Capitalización bursátil
$9.87K
Cambio (1 día)
0.00%
Cambio (1 año)
-99.79%
País
CA
Comercio Valeo Pharma Inc. (VPHIF)

Categoría

Ratio P/B de Valeo Pharma Inc. (VPHIF)
Ratio P/B al 2026 TTM: 0
Según los informes financieros más recientes y el precio de las acciones de Valeo Pharma Inc., el ratio P/B actual (TTM) es 0. Al final de 2026, el ratio P/B era 0.
Historial del ratio P/B de Valeo Pharma Inc. desde 2026 hasta 2026
Ratio P/B al final de cada año
Año Ratio P/B Cambiar
Not enough data for the provided dates.
Ratio P/B de empresas similares o competidoras